Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies (vol 54, pg 1226, 2015)

被引：1
|
作者：
Kvamme, Maria K. [1 ,2 ,3 ]
Lie, Elisabeth [1 ]
Uhlig, Till [1 ]
Moger, Tron A. [2 ]
Kvien, Tore K. [1 ]
Kristiansen, Ivar S. [2 ]
机构：
[1] Univ Oslo, Diakonhjemmet Hosp, Dept Rheumatol, Oslo, Norway
[2] Univ Oslo, Dept Hlth Management & Hlth Econ, Oslo, Norway
[3] Norwegian Knowledge Ctr Hlth Serv, POB 7004 St Olavs Plass, N-0130 Oslo, Norway
来源：
RHEUMATOLOGY | 2020年 / 59卷 / 04期
关键词：
D O I：
10.1093/rheumatology/kez609
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：917 / 917
页数：1
相关论文
共 29 条
  • [21] Clinical predictors of inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) including methotrexate (MTX) in untreated rheumatoid arthritis patients: A single-center observational study.
    Aramaki, Toshiyuki
    Ueki, Yukitaka
    Kojima, Kanako
    Kurushima, Shota
    Tsuji, Yoshika
    Kawachi, Natsumi
    Iwamoto, Naoki
    Ichinose, Kunihiro
    Terada, Kaoru
    Eguchi, Katsumi
    Kawakami, Atsushi
    MODERN RHEUMATOLOGY, 2020, 30 (01) : 50 - 57
  • [22] 6 Claims-Based Analysis of Cost-Effectiveness Among Patients with Rheumatoid Arthritis Who Switched from a Tumor Necrosis Factor Inhibitor to Another Targeted Disease-Modifying Antirheumatic Drug
    Bonafede, Machaon
    Wei, Wenhui
    Chen, Chieh-I
    McMorrow, Donna
    Fiore, Stefano
    Fay, Jonathan
    Kimura, Toshio
    Curtis, Jeffrey R.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [23] Major adverse cardiovascular events or venous thromboembolism in patients with rheumatoid arthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a nationwide, population-based cohort study
    Kao, Chung-Mao
    Chen, Yen-Ju
    Chen, Yi-Ming
    Chen, Der-Yuan
    Chen, Hsin-Hua
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2025, 17
  • [24] Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice (vol 34, pg 563, 2015)
    Bykerk, Vivian P.
    Oestoer, Andrew J. K.
    Alvaro-Gracia, Jose
    Pavelka, Karel
    Roman Ivorra, Jose Andres
    Graninger, Winfried
    Bensen, William
    Nurmohamed, Michael T.
    Krause, Andreas
    Bernasconi, Corrado
    Aassi, Maher
    Sibilia, Jean
    CLINICAL RHEUMATOLOGY, 2015, 34 (07) : 1321 - 1321
  • [25] Sustained Response in a Phase 3 Study of Sarilumab Plus Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients with Active, Efficacy of Sarilumab in Combination with Csdmards in Patients with Rheumatoid Arthritis and Inadequate Response to TNF Inhibitors By Baseline Levels of Disease Activity
    Fleischmann, Roy
    van Hoogstraten, Hubert
    Jayawardena, Shyamalie
    Mangan, Erin K.
    Ching, Daniel
    Burmester, Gerd R.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [26] Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance database
    Sakai, Ryoko
    Tanaka, Eiichi
    Inoue, Eisuke
    Harigai, Masayoshi
    RMD OPEN, 2024, 10 (02):
  • [27] Impact of Multimorbidity on Targeted Synthetic and Biologic Disease-modifying Antirheumatic Drug (ts/bDMARD) Effectiveness in Patients with Rheumatoid Arthritis: A Two Year Follow-up Study from Mexican Adverse Events Registry BIOADAMEX
    Rivera Teran, Vijaya
    Vega Morales, David
    Colunga Pedraza, Iris Jazmin
    Sicsik Ayala, Sandra
    Castillo Ortiz, Angel Alejandro
    Saavedra Salinas, Miguel Angel
    Miranda Hernandez, Dafhne
    Irazoque Palazuelos, Fedra
    Casasola Vargas, Julio Cesar
    Munoz Monroy, Omar Eloy
    Carrillo Vazquez, Sandra
    Merayo Chalico, Javier
    Guaracha Basanez, Guillermo
    Torres Valdez, Estefania
    Valdes Corona, Luis
    Pena Ayala, Angelica
    Duran Barragan, Sergio
    Ramos Sanchez, Azucena
    Paz Viscarra, Aleni
    Zamora Tehozol, Erick Adrian
    Xibille Friedman, Daniel
    Torres Ruiz, Jiram
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 3870 - 3872
  • [28] Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan (vol 27, pg 755, 2017)
    Mimori, T.
    Harigai, M.
    Atsumi, T.
    Fujii, T.
    Kuwana, M.
    Matsuno, H.
    MODERN RHEUMATOLOGY, 2017, 27 (05) : V - V
  • [29] Effect of a 12-week high-intensity exercise intervention: a comparison of cardiac exercise adaptations during biological disease-modifying antirheumatic drug treatment (TNF inhibitors vs IL-6 signalling inhibitors) in patients with rheumatoid arthritis - study protocol for a randomised controlled trial
    Jonck, Simon
    Adamsen, Malte Lund
    Hojgaard, Pil
    Rasmussen, Iben Elmerdahl
    Ellingsgaard, Helga
    Lund, Morten Asp Vonsild
    Jorgensen, Peter Godsk
    Jacobsen, Soren
    Kober, Lars
    Vejlstrup, Niels
    Dreyer, Lene
    Pedersen, Bente Klarlund
    Berg, Ronan M. G.
    Christensen, Regitse Hojgaard
    BMJ OPEN, 2023, 13 (05):
123